Home / Letter From The Editor / Nov. 8, 2018

Nov. 8, 2018

Nov 8, 2018
 

This week the Food and Drug Administration has approved the product canagliflozin to reduce the risk of major adverse cardiovascular events, including heart attack, stroke or death due to a cardiovascular cause in adults with Type 2 diabetes who have established cardiovascular disease. Although we are all familiar with the cardiovascular benefits of the SGLT-2 Inhibitors, this is the first time the FDA has said that an SGLT-2 Inhibitor can reduce the risk.

The good things about this class of drugs continue to increase, as you can see in this month’s Therapy Edition.

Dave Joffe

Editor-in-chief